Speakers
Paul Kalra, Consultant Cardiologist and Heart Failure Specialist, Portsmouth Hospitals NHS Trust, UK
Learning objectives
- Interpret new data surrounding the use of cardiac myosin inhibitors in patients with hypertrophic obstructive cardiomyopathy.
- Understand some of the issues surrounding timely diagnosis in patients with de novo heart failure.
- Recognise guidelines and new data around intravenous iron (ferric carboxymaltose or ferric derisomaltose) to enhance quality of life and reduce hospitalisation in heart failure patients with reduced or mildly reduced ejection fraction.
- Understand the prospect of potassium binders and their potential role in helping to maintain mineralocorticoid receptor antagonist use in patients with, or at high risk of, hyperkalaemia.
